Skip to main content
2024 CNSF Congress Main banner
Neuro|News Annual Edition
Final Program


Calendar-of-Events
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Evaluation

Industry Supported Session

Lunch 'n Learn: Optimizing newborn screening and emerging clinical data in the evolving care of SMA

Thursday, May 23, 2024
12:00 PM – 1:30 PM EST
Location:CF: Ontario

Audience:

Adult Neurologist, Child Neurologist, Neurosurgeon, Neuroradiologist, Neurophysiologist, Resident, Fellow, Nurses with interest in topic

Learning Level:

Intermediate (Practicing Physician), Advanced (Special Interest, Higher Level Discussion)

Learning Format:

Audience response system, Case studies, Forum/panels, Lecture/plenary method, Question and answer sessions, Seminar

CanMEDs Roles:

Medical Expert, Scholar, Communicator, Collaborator, Professional

The implementation of newborn screening for spinal muscular atrophy (SMA) has had a significant impact on clinical management of the disease. This course will provide details about how the steps involved with newborn screening have been optimized in different provinces and discuss how this impacts patient care and the multidisciplinary care teams. In addition, this course will review recent clinical trial results and highlight the important role of registry and real-world data in the clinical management of SMA.

This program was developed by the CNSF and Novartis and was planned to achieve scientific integrity, objectivity and balance. It is an unaccredited learning activity and not eligible for MOC credits.

Learning Objectives:

  • Better understand the evolving SMA patient journeys in Canada and the role(s) and composition of the multidisciplinary care teams
  • Recognize the steps involved with newborn screening for SMA and how time-to-treatment can be optimized in provinces
  • Review recent clinical trial results and emerging registry and real-world data for the clinical management of SMA in Canada

Presentations:

  • 12:00 PM – 12:20 PM EST
    The first 4 years of SMA screening in Ontario: Key learnings from the lab

    Faculty: Pranesh Chakraborty

  • 12:20 PM – 12:40 PM EST
    Newborn screening and the need for rapid diagnosis and treatment: Clinical impacts

    Faculty: Kathryn Selby

  • 12:40 PM – 1:00 PM EST
    New clinical data and emerging treatment considerations for SMA

    Faculty: Hugh McMillan

  • 1:00 PM – 1:30 PM EST
    Q&A

    Faculty: Pranesh Chakraborty

    Faculty: Kathryn Selby

    Faculty: Hugh McMillan